In this issue of Blood, McLaughlin et al demonstrate the safety and efficacy of donor-derived Epstein-Barr virus (EBV) latent membrane protein (LMP)-specific T cells to prevent relapse of aggressive EBV-positive B- or T/NK-cell lymphomas following allogeneic hematopoietic stem cell transplantation (HSCT).(1)
机构:
Swansea Bay Univ Hlth Board, All Wales Lymphoma Panel, Swansea, W Glam, Wales
Swansea Univ, Swansea, W Glam, WalesSwansea Bay Univ Hlth Board, All Wales Lymphoma Panel, Swansea, W Glam, Wales
Dojcinov, Stefan D.
Quintanilla-Martinez, Leticia
论文数: 0引用数: 0
h-index: 0
机构:
Eberhard Karls Univ Tubingen, Univ Hosp Tubingen, Inst Pathol & Neuropathol, Tubingen, Germany
Eberhard Karls Univ Tubingen, Univ Hosp Tubingen, Comprehens Canc Ctr Tubingen, Tubingen, GermanySwansea Bay Univ Hlth Board, All Wales Lymphoma Panel, Swansea, W Glam, Wales
机构:
Caritas Med Ctr, Dept Pathol, Shamshuipo, Kowloon, Hong Kong, Peoples R ChinaCaritas Med Ctr, Dept Pathol, Shamshuipo, Kowloon, Hong Kong, Peoples R China